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Abstract   
Correlation between Protease activated receptor 1 (Par1) polymorphism and 
recurrent abortion in Palestine 
 
Recurrent abortion (RA), affects 5% of women in their reproductive age in the first 
trimester of pregnancy.  Although there are many causes for RA, a definite reason for the 
repeated miscarriage is still unknown in half of the cases.  During placental invasion 
period, the expression of human protease activated receptor 1 (PAR1) peaks in vivo 
between the 7th -10th weeks of gestation and completely shuts off thereafter.  Also, PAR1 
is crucial to many important processes involved in placentation, and its polymorphisms 
were found to correlate with different diseases and unfavorable pregnancy outcomes.  For 
that we aimed to find out the correlation between Par1 polymorphisms and RA.   
Our case-control study included 175 females from the north and the center areas of 
Palestine with two or more consecutive first-trimester miscarriages as cases and 241 
females with two or more normal ended deliveries from the same ethnic background as 
controls.  The research was carried out at Al - Quds Nutrition and Health Research 
Institute, Al - Quds University, Abu- Dies (2009-2010).  DNA was extracted from blood 
samples of participants and analyzed for polymorphisms in the 5′ regulatory region of 
Par1, namely -506 Insertion/ Deletion (I/D) (rs11267092) and -1426 C/T (rs32934).  The -
506 I/D was analyzed by size polymorphic Polymerase chain reaction (PCR).  The -1426 
C/T polymorphism was analyzed by Restriction Fragment Length Polymorphism (RFLP), 
High resolution melting (HRM) and by direct sequencing for quality control purposes.  To 
make it technically easier we made major modifications on published techniques used to 
genotype these polymorphisms. Indeed, our results showed that our modified techniques 
are reliable and easier to implement than published ones, especially the HRM which is an 
inexpensive, time saving, and high throughput method of analysis. 
The polymorphisms inspected in this study showed no deviation from Hardy – Weinberg 
equilibrium.  The minor allele frequency I for the -506 I/D polymorphism was 0.328 and 
0.376 for cases and controls respectively (allelic OR 0.8; 95% CI= 0.6 -1.1, p 0.155).  The 
minor allele frequency T for the –1426 C/T polymorphism was 0.012 and 0.009 for cases 
v 
and controls respectively (allelic OR 1.3; 95% CI= 0.8 -8.0, p 1.0).  Our results showed no 
association between Par1 polymorphisms (rs11267092 and rs32934) and RA.   
Although our results showed no association between the polymorphisms we tested and RA, 
we think our study is valuable since we developed easier techniques that can be used to 
screen for these polymorphisms where their presence is associated with other diseases.  
Moreover, we ruled out the possibility that these polymorphisms could have association 
with RA in our population, although association was found between them and different 
unfavorable pregnancy out comes, in addition to different diseases in different ethnic 
groups.  Nonetheless, there is still an open question whether these or other polymorphisms 
in Par 1 gene could have association with unfavorable pregnancy out comes, in our 
population, if analyzed on the fetus tissue and not maternal tissue only.  
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Chapter one 
 
1.1 Introduction 
 
Recurrent abortion (RA), defined as two or more consecutive spontaneous abortion, affects 
5% of women in their reproductive age in the first trimester of pregnancy (Allison and Schust, 
2009; Kovalevsky et al., 2004).  While RA was found to correlate with chromosomal 
abnormalities, thrombophilia, metabolic disorders, anatomical causes, infectious diseases, and 
immune factors (Horne and Alexander, 2005), a definite reason for the repeated miscarriage 
is still unknown in up to 50% of cases (Allison and Schust, 2009).  
 
Placentation, a normal physiological invasion process, in which cytotrophoblasts (CTB), 
specialized epithelial cells, differentiate, proliferate, and invade the decidua and the spiral 
arteries (Cross et al., 1994; Even-Ram et al., 2003).  Proper placentation and maintenance of 
adequate placental circulation is important for successful pregnancy (Dudding and Attia, 
2004).  The CTB in their invasion process share many features with tumor cells in term of 
metastasis, growth, search for blood supply, and extracellular matrix (ECM) degradation 
(Cross et al., 1994; Damsky and Fisher, 1998).  These properties are critical for appropriate 
feto-maternal interaction and should be tightly controlled (Damsky and Fisher, 1998; Even-
Ram et al., 2003; Flamigni et al., 1991; Yin et al., 2003a).  It has been reported that Protease 
Activated Receptor 1 (PAR1) is exclusively and transiently expressed in CTB during their 
invasion (Even-Ram et al., 1998).  Moreover, it has been shown that PAR1 plays an 
important role in pathologic and physiologic invasion processes (Even-Ram et al., 1998). 
 
PAR1, a seven transmembrane G-protein coupled receptor (GPCR), belongs to the PAR 
family (Grand et al., 1996).  PAR1 is the main thrombin receptor on vascular cells and 
plays an important role in haemostasis, inflammation and vascular development (Coughlin, 
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2000; Traynelis and Trejo, 2007).  Recent studies have advanced our knowledge about the 
important role that PAR1 plays in tumor development, metastasis, and angiogenesis (Even-
Ram et al., 1998; Yin et al., 2003a; Yin et al., 2003b).  It has been noticed that PAR1 is 
exclusively expressed between the 7th- 10th weeks of gestation and completely shut off 
thereafter (undetectable by the 12th week), suggesting a temporal and critical relationship 
between the expression of PAR-1 and early placentation (Even-Ram et al., 2003).  
Polymorphisms of Par1 gene have been reported to have physiologic relevance (Altarescu 
et al., 2010; Arnaud et al., 2000; Dupont et al., 2003; Grisaru-Granovsky et al., 2007; 
Martinelli et al., 2008).  The temporal expression of PAR1 during placental formation 
should be tightly controlled for appropriate feto-maternal interaction, for that, any 
polymorphism in Par1 may influence critical processes involved in placentation resulting 
in an improper feto-maternal interaction and consequently adverse pregnancy outcome 
(Grisaru-Granovsky et al., 2007).   
 
1.2 Justification 
 
Since its discovery in 1991, extensive research studies have identified PAR1 as an 
important player in different pathologic and physiologic situations.  It has been shown that 
PAR1 plays an important role in blood coagulation and homeostasis (Coughlin, 2000).  It 
has been shown that 50% of Par1 Knockout mouse embryos die as a result of multiple 
bleeding and cardiovascular failures at embryonic days 9-10 (E9-10), suggesting that 
PAR1 and coagulation factors may contribute to normal blood vessel development (Griffin 
et al., 2001).  Moreover, PAR1 has been shown to be involved in the modulation of the 
extracellular matrix during placentation (Even-Ram et al., 2003).  Needless to say, that all 
these processes are critical for successful placentation.  In normal placentation the 
expression of PAR1 on CTB peaks in vivo between the 7th -10th weeks of gestation and 
completely shuts off after that (Even-Ram et al., 2003).  This time coincides with the 
maximal invasion of CTB and the increased production of matrix metalloproteases and 
urokinase–type plasminogen activator (Cohen et al., 2006; Xu et al., 2000).  The central 
role of PAR1 in tumor invasiveness and metastasis has been derived from different studies.  
PAR1 plays an important role during metastatic breast carcinoma cell invasion and 
prostate cancer progression by enhancing both angiogenesis and tumor growth (Salah et 
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al., 2005; Yin et al., 2003a).  The pathobiology of several pregnancy disorders is associated 
with dysregulantion of CTB invasion (Even-Ram et al., 2003).  Therefore, due to the fact 
that PAR1 is crucial for many important processes involved in placentation, and since 
polymorphism in its gene was found to correlate with different diseases and unfavorable 
pregnancy outcomes (Grisaru-Granovsky et al., 2007), we suggest that such polymorphism 
(-506 I/D and -1426 C/T)  might correlate with RA.  
 
1.3 Problem Statement 
 
Despite the fact of high fertility rate among Palestinian females, which according to the 
Palestinian Ministry Of Health (MOH) in its executive summary 2003 was calculated to be 
3.89 (4.7 in Gaza Strip and 3.4 in West Bank), yet, the problem with RA is still present.  
Although no statistical data is available in our country about the prevalence of RA, except 
the one done by the UNRWA, many women are still going to local clinics for treatment of 
RA with no pregnancy success.  According to UNRWA, 4 - 8 % of women attending the 
UNRWA antenatal care unit in the north part of the west bank, suffer from RA (Abu-Hilal, 
2009).  While RA might be related to chromosomal abnormalities, thrombophilia, 
metabolic disorders, anatomical causes, and immune factors, the etiology in 50% of the 
cases is still unknown (Horne and Alexander, 2005).  Though, more research must be 
focused toward the identification of further risk factors in order to find the appropriate 
treatment, and prevent over treatment of an enormous number of women who receive 
either low molecular weight heparin or hormonal treatment as prophylactic protocols to 
prevent RA (Dudding and Attia, 2004; Horne and Alexander, 2005).  Here, we suggest 
testing the correlation between Par1 polymorphism (-506 I/D and -1426 C/T) - a gene 
known to be involved in pathological and physiological invasion processes like 
placentation – and RA.  
 
1.4 Goals 
 
The main objective of this work is to investigate the association between Par1 gene 
polymorphism in the 5′ regulatory region (-506 I/D and -1426 C/T) and RA among 
Palestinian females in the West Bank.  This study also aims to develop a cost effective and 
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advanced technique for genotyping these polymorphisms using High Resolution Melting 
(HRM) one of the Real-Time Polymerases Chain Reaction (RT-PCR) for the -1426 C/T (rs 
32934) SNP and size polymorphic RCR for the -506 I/D (rs 11267092). 
 
1.5 Questions 
 
 Par1 gene polymorphisms (-506 I/D and -1426 C/T) and recurrent abortion…is there a 
relationship? 
 High Resolution Melting (HRM) is a new molecular technique to detect single 
nucleotide polymorphisms (SNPs).  Could it be applicable for detecting -1426 C/T (rs 
32934) SNP? 
 What is the allele frequency of Par1gene polymorphisms (-506 I/D and -1426 C/T) 
among the Palestinian female population? 
 
1.6 Hypothesis 
 
PAR-1 is highly expressed in the 7th - 10th weeks of gestation and shut down thereafter, 
this period is coincided with embryonic implantation and placental formation.  Moreover, 
PAR1 has been shown in different invasion events and in processes critical for 
placentation.  Thus, we hypothesize that Par1 polymorphisms (-506 I/D and -1426 C/T) 
that might alter the expression of this gene could lead to unfavorable pregnancy outcomes, 
including RA.  
 
1.7 Scientific Background 
 
1.7.1 Recurrent abortion  
 
Recurrent abortion (RA), traditionally has been defined as three or more consecutive 
pregnancy losses at less than 20 weeks of gestation (Allison and Schust, 2009; Pabinger, 
2009; Perni et al., 2004).  Recently, the Practice Committee of the American Society for 
Reproductive Medicine (ASRM) in January 2008 and the ASRM Board of Directors in 
February 2008 have redefined RA as “two or more failed pregnancies” (ASRM, 2008).  
RA affects 5% of women in their reproductive age (Kovalevsky et al., 2004; Lissalde-
5 
Lavigne et al., 2005; Sierra and Stephenson, 2006).  While RA was found to correlate with 
chromosomal abnormalities, thrombophilia, metabolic disorders, anatomical causes, 
infectious diseases, and immune factors , the etiology in half of cases remains vague, 
figure (1.1) (Ford and Schust, 2009; Horne and Alexander, 2005).  RA could be named as 
recurrent pregnancy loss (RPL) (Kutteh and Triplett, 2006), recurrent miscarriage (Horne 
and Alexander, 2005; Li et al., 2002; Rai and Regan, 2006), recurrent spontaneous 
abortion (Perni et al., 2004) and habitual abortion (Gruber and Huber, 2005).  
 
1.7.1.1 Causes of RA 
 
1.7.1.1.1 Genetic factor 
 
About 2% to 5% of RA is associated with a parental balanced structural chromosome 
rearrangement (Allison and Schust, 2009; Ford and Schust, 2009).  Chromosomal 
translocation either reciprocal or robertsonian are most frequently encountered (Clifford et 
al., 1994; Horne and Alexander, 2005).  Although these parents are phenotypically normal 
, 50% - 70 % of their gametes and consequently their embryos are unbalanced due to 
abnormal separation at meiosis leading to pregnancy termination (Rai and Regan, 2006). 
Aneuploid embryos may be another cause of RA; it is more common with advanced 
reproductive age reflecting decreased quality oocytes (Sierra and Stephenson, 2006; Vidal 
et al., 1998).  X-chromosome inactivation has been reported to be a cause of RA (Uehara et 
al., 2001)   
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Figure 1.1: Etiology of recurrent pregnancy loss.  APS, antiphospholipid syndrome.  
Adopted from (Ford and Schust, 209). 
 
1.7.1.1.2 Metabolic disorders 
 
Endocrine disorders are heterogeneous, involved in around 17% to 20% of RA (Ford and 
Schust, 2009).  Prolactin plays a role in both ovulation and endometrial maturation (Bussen 
et al., 1999; Rai and Regan, 2006).  Hyperprolactinaemia and lack of endometrial prolactin 
expression during the luteal phase of the menstrual cycle have been reported to be 
associated with RA (Hirahara et al., 1998; Rai and Regan, 2006).  Hypo- and 
hyperthyroidism have also been associated with fetal loss (Kaprara and Krassas, 2008).  
Uncontrolled diabetes mellitus and insulin resistance is common in women with RA (Craig 
et al., 2002; Roberts and Murphy, 2000).  Alternatively, well –controlled diabetes mellitus 
and treated thyroid dysfunction is not associated with RA (Clifford et al., 1994).  
Polycystic ovarian syndrome (PCOS) has been associated with RA (Rai et al., 2000).  
Recently , PCOS and its association with insulin resistance have been noted as a cause of 
RA (Ford and Schust, 2009; Rai and Regan, 2006).  Increased androgen level in the 
follicular phase has also been reported to be associated with RA (Bussen et al., 1999; Okon 
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et al., 1998).  Increased levels of luteinizing hormone (LH) is suggested to be a cause of 
RA (Clifford et al., 1994; Homburg et al., 1988), others however, did not recommend LH 
hypersecretion to be a cause of RA (Bussen et al., 1999; Li et al., 2000).  These 
contradicting results may be related to the more specific and more sensitive methods of 
detection and the sampling time (Li et al., 2002).  
 
1.7.1.1.3 Thrombophilia 
 
Thrombophilia either acquired and/or hereditary, predispose patients to thromboembolic 
events (Kutteh and Triplett, 2006; Li et al., 2002).  Pregnancy itself is considered as 
secondary hypercoagulable state (Kutteh and Triplett, 2006; Rai and Regan, 2006).  
Recently, several studies have been carried out to find an association between different 
causes of thrombophilia and RA and yielded controversial results.  For that, different meta-
analysis studies were carried out to reveal these contradiction (Dudding and Attia, 2004; 
Kist et al., 2008; Kovalevsky et al., 2004; Rey et al., 2003).  These studies revealed a 
strong association between RA in the second /third trimester and carriers of factor V 
Leiden (FVL) (Dudding and Attia, 2004; Kist et al., 2008).  Others revealed an association 
between carriers of FVL, activated protein C resistance, and prothrombin mutation in the 
first trimester of pregnancy with stronger association in late pregnancy trimesters 
(Kovalevsky et al., 2004; Rey et al., 2003).  Ethnicity and disease severity may interpret 
these diverse results (Kist et al., 2008).  Females homozygous for the methyltetrafolate 
reductase mutation (MTHFR) are not at risk for RA (Pabinger, 2009; Rey et al., 2003).  
However, patients suffering from Antiphospholipid syndrome (APS) -acquired 
thrombophilia- with Antiphospholipid Antibodies (APAs) are at high risk concerning RA 
(Kutteh and Triplett, 2006; Pabinger, 2009).  As these antibodies may impair trophoblast 
invasion and promote trophoblast apoptosis (Rai and Regan, 2006). 
 
1.7.1.1.4 Anatomical causes. 
 
Congenital and acquired uterus abnormalities are another cause of RA and are related to 
10% to 15% of RA causes (Ford and Schust, 2009).  Congenital abnormalities as in 
Müllerian anomalies have been implicated with septate uterus (Propst and Hill, 2000).  
This will lead to RA as a result of reduced sensitivity to steroid hormones (Fedele et al., 
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1996; Horne and Alexander, 2005) and inadequate blood supply to the developing embryo 
and placenta (Propst and Hill, 2000).  Asherman’s syndrome or endometrial fibrosis is an 
acquired problem in which uterine cavity is partially or completely obliterated , resulting in 
improper implantation, decreased sensitivity to steroid hormones, interruption of blood 
supply to the uterus and/or no space for the fetus to develop and grow (Horne and 
Alexander, 2005; Li et al., 2002).  
 
1.7.1.1.5 Immune factors 
 
Since the fetus is genetically not identical to his mother, immunological factors may be an 
important etiology concerning RA (Ford and Schust, 2009; Horne and Alexander, 2005).  
For that, the presence of cytotoxic antibodies, inappropriate sharing of human leukocyte 
antigens, absence of maternal blocking antibodies and disturbances in natural killer cell 
function and allocation may be different causes of RA (Allison and Schust, 2009).  
Autoantibodies are more commonly encountered antibodies in patients with RA (Horne 
and Alexander, 2005; Rai and Regan, 2006).  APAs are being the mostly encountered 
(Greaves et al., 2000; Rai and Regan, 2006).  The presence of thyroid antibodies may be 
related to increased risk of RA as these antibodies reveal a generalized activation of the 
immune system against the feto-placental unit (Kaprara and Krassas, 2008; Pratt et al., 
1993).  
  
1.7.1.1.6 Infections  
 
Infection is an infrequent cause of RA (Summers, 1994).  For an infective agent to be 
involved as a cause of RA, it must persist in the genital tract and cause some maternal 
symptoms (Rai and Regan, 2006).  While TORCH (Toxoplasmosis, Rubella, Cytomegalo-
virus and Herpes) infections have been reported to be implicated in adverse pregnancy 
outcome and miscarriage (Gilbert, 2002), routine screening for them is not recommended 
in RA (Horne and Alexander, 2005; Li et al., 2002; Rai and Regan, 2006).  The presence 
of high titer immunoglobulin G antibody to Chlamydia trachomatis has been reported to be 
associated with RA (Baud et al., 2008; Witkin and Ledger, 1992). 
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1.7.1.1.7 Undefined causes.  
 
 A definite reason for the repeated miscarriage is still unknown in up to 50% of cases 
(Allison and Schust, 2009; Horne and Alexander, 2005; Li et al., 2002). 
 
1.7.1.2 Placentation 
  
Embryonic development requires a placenta that forms by implantation of the blastocyst in 
the maternal uterus (Tarrade et al., 2001).  The placenta is an independent and temporary 
organ that allows nutrition and gas exchanges between the fetus and the maternal body 
(Tarrade et al., 2001).  Placentation requires a sequence of complex, coordinated interac-
tions between CTB and the maternal uterus (Xu et al., 2000).  An important aspect of this 
process is the invasion of the CTB into the maternal decidua and the spiral arteries (figure 
1.2) (Le Bouteiller and Tabiasco, 2006; Yin et al., 2003a).  A successful pregnancy 
outcome depends strictly on proper placentation and maintenance of sufficient placental 
circulation (Dudding and Attia, 2004).  Therefore, it is possible that any abnormalities in 
placental formation or vasculature may lead to improper placentation or inadequate feto-
maternal circulation resulting in adverse pregnancy outcome (Dudding and Attia, 2004).  It 
has been demonstrated that any dysregulation in CTB invasion will lead to several 
disorders of pregnancy (Yin et al., 2003a), for instance, preeclampsia and restriction of 
fetal growth are associated with shallow uterine invasion (Zhou et al., 1993), while partial 
or complete hydatidiform moles and choriocarcinoma are associated with excessive 
proliferation and invasion (Even-Ram et al., 2003; Yin et al., 2003a) .  A critical feature in 
CTB invasion is their interaction with the surrounding ECM, which is characterized by 
specific cell adhesion molecule profile switching (Damsky and Fisher, 1998; Zhou et al., 
1993).  This includes the down regulation of and E-cadherin that are characteristics 
of stable epithelial monolayer (Zhou et al., 1993), and the up regulation of vand 
VE cadherin that mimic the endothelial cells phenotype (Zhou et al., 1993).  It has been 
shown that the abnormality in adhesion – related to antigen expression– may be due to the 
abnormal expression of regulatory molecules produced by the trophoblast or the maternal 
cells with which they come in contact (Zhou et al., 1993).  The CTB in their invasion 
process share many features with tumor cells in term of metastasis, growth, search for 
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blood supply and ECM degradation; these properties critical for appropriate feto-maternal 
interaction and should be tightly controlled (Damsky and Fisher, 1998; Even-Ram et al., 
2003; Flamigni et al., 1991; Yin et al., 2003a).    CTB invasion, unlike tumor cells, is 
precisely regulated to be spatially constricted to the inner third of the myometrium and 
temporally restricted to early pregnancy (Xu et al., 2000).  In CTB invasion, placental 
microenvironment remodeling and trophoblast out growth are needed where these effects 
are carried out by serine and matrix metalloproteases (MMPs) (Cohen et al., 2006; Xu et 
al., 2000).  It has been reported that MMP-9 secretion increases gradually from the 7th -
11th weeks of gestation with the maximal invasive potential of CTB (Xu et al., 2001; Xu et 
al., 2000).  This gradual increase coincides with the over expression of the Protease 
Activated Receptor1 (PAR1) which plays an important role in pathologic and physiologic 
invasion processes (Even-Ram et al., 1998; Grisaru-Granovsky et al., 2007).  
 
 
 
 
Figure 1.2 Placentation.  Cytotrophoblasts (CTB) differentiate, proliferate, and invade into 
the maternal decidua and the spiral arteries.  Adopted from (le Bouteiller, 2006), with 
modification. 
 
CTB invasion
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1.7.1.3 Protease Activated Receptors 
 
PAR1, a seven transmembrane G-protein coupled receptor (GPCR), belongs to the PAR 
family (Coughlin, 2000; Hirano and Kanaide, 2003; Vu et al., 1991).  PARs are found to 
be expressed on a variety of cell types and tissues such as platelets, endothelial cells, 
sensory neurons, fibroblast, vascular and nonvascular smooth muscles (O'Brien et al., 
2008).  Multiple extracellular proteases can activate PARs; thrombin is the physiological 
activator of PAR1, PAR3 and PAR4 (Coughlin et al., 1992; Grand et al., 1996).  Other 
proteases can activate the receptors and may contribute to their function in vivo such as 
activated protein C (APC) (Mosnier et al., 2007; Riewald et al., 2002), anticoagulant 
proteases plasmin, cathepsin G (Traynelis and Trejo, 2007) and MMPs family (Boire et al., 
2005; Trivedi et al., 2009).  PAR-2, on the other hand, cannot be activated by thrombin and 
require trypsin-like protease for activation as trypsin (Nystedt et al., 1994), tryptase 
(Molino et al., 1997), factor VIIa and factor Xa (Camerer et al., 1996).  PARs are activated 
by an N-terminus cleavage that exposes a tethered ligand which autoregulates the receptor 
by coupling it to the G protein (Chen et al., 1994; Traynelis and Trejo, 2007).  This 
activation is important for the hydrolysis of the structural proteins at the ECM, engagement 
of integrins, cell adhesion and mitogenesis (Boire et al., 2005; Grand et al., 1996; Martorell 
et al., 2008).   
 
1.7.1.3.1 PAR1 
 
Human thrombin receptor was isolated from cDNA cloned in Xenopus oocytes (Vu et al., 
1991).  PAR1 consists of seven helical hydrophobic transmembrane regions (Vu et al., 
1991).  This assembly gave rise to three intracellular loops with C- terminal tail and three 
extracellular loops with long N-terminal domain, figure (1.3) (Grand et al., 1996).  This 
long N-terminal domain is important for receptor recognition and cleavage (Vu et al., 
1991).  
 
PAR1, also known as Factor 2 receptor (F2R) (O'Brien et al., 2008) or human thrombin 
receptor (Li et al., 1996).  It spans about 27-kilobase (kb) on chromosome number 5q11.2 
to q13.3 (Arnaud et al., 2000; Schmidt et al., 1996) , with Genbank accession number 
AF054633.1 (http://www.ncbi.nlm.nih.gov/nuccore/3309036).  It consists of two exons 
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and a single intron (around 22 kb in size) (Dupont et al., 2003; Schmidt et al., 1996).  
PAR1 encodes 425 amino acids (Vu et al., 1991). Of which, 29 amino acids are encoded in 
the first exon, while the majority of the coding sequence and the thrombin cleavage site are 
located in the second exon (Schmidt et al., 1996).  Within the proximal promoter, multiple 
transcription initiation sites are located with the absence of a TATA box sequence (Li et 
al., 1996). 
 
1.7.1.3.1.1 PAR1 activation 
 
PAR 1 is considered as a peptide receptor that carries its own ligand which become 
exposed upon receptor cleavage (Coughlin, 1999a).  PAR1 cleavage site resides in the 
amino-terminal extracellular domain between amino-acids arginine 41 and serine 42 (Vu et 
al., 1991).  Once cleavage takes place, a new receptor amino terminal started with the 
sequence SFLLRN (Serine- phenylalanine- leucine- leucine – arginine - aspargine) is 
generated and functions as a tethered ligand (Vu et al., 1991).  This newly exposed N-
terminus interacts with a binding site located on amino acid 244- 268 in the second 
extracellular loop and activates the receptor (Bahou et al., 1994; Gerszten et al., 1994; 
O'Brien et al., 2001) (figure 1.3).  Synthetic hexapeptide SFLLRN or pentapeptide SFLLR, 
that resembles the newly formed amino-terminus, or modified sequence TRAPs (thrombin 
receptor-activating peptides), can fully activate the receptor independent of receptor 
cleavage (Anderluh and Dolenc, 2002; Chen et al., 1994; Sabo et al., 1992).  Although 
thrombin and TRAPs can activate PAR1, different concentration from them are required to 
elicit the same response (Grand et al., 1996).  Although thrombin is considered the main 
physiological activator for PAR1 (Vu et al., 1991), other proteases can activate the receptor 
and elicit intracellular signaling.  Among these proteases, APC (Riewald et al., 2002), 
anticoagulant proteases plasmin, cathepsin G (Traynelis and Trejo, 2007) and MMPs 
family (Boire et al., 2005; Trivedi et al., 2009). 
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Figure1.3: PAR1 structure and activation mechanism. PAR1, a seven transmembrane 
bound receptor.  Thrombin recognition site resides in the amino-terminal extracellular 
domain; the newly formed amino-terminal will bind to the second extracellular loop and 
activates the receptor.  Adopted from (Coughlin, 2005). 
 
1.7.1.3.1.2 PAR1 signaling  
 
Once activated, PAR1 undergo conformational changes to facilitate coupling to 
heterotrimeric G-protein (Coughlin, 1999a).  PAR1 couples to Gq, Gi, G12/13 and 
G families (Coughlin, 2000).  This will induce activation of diverse signaling cascades 
and elicit different cellular responses figure (1.4) (Coughlin, 2005; Hirano and Kanaide, 
2003).  Coupling to G12/13 subunits will lead to guanine nucleotide exchanging factors 
(GEFs) binding and activation of Rho kinase, serine/threonine-specific protein, resulting in 
platelets’ shape change (Angiolillo et al., 2010).  On the other hand, coupling to Gq 
activates phospholipase C that leads to phosphoinositide hydrolysis and the production of 
inositol (1, 4, 5)-triphosphate (IP3) and diacylglycerol (DAC) (Arora et al., 2007; 
Coughlin, 2005).  This will cause mitogen-activated protein (MAP) kinases activation, 
mobilization of intracellular Ca2+, and protein kinase C activation (Arora et al., 2007; 
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Coughlin, 2000).  Adenylyl cyclase inhibition is a result of Gi coupling (Coughlin, 
2005).  Coupling to G will activate phosphoinositide-3 kinase (PI3 kinases), ions 
channels, and G-protein coupled receptor kinases (GRKs) (Coughlin, 2005). 
 
 
 
Figure1.4:  PAR1 signaling.  Once the newly formed amino terminal binds to its receptor, 
coupling to PAR1 Gq, Gi, G12/13 and G families takes place. This will lead to 
activation of diverse signaling cascades and eliciting different cellular responses.  Adopted 
from (Coughlin, 2005). 
 
1.7.1.3.1.3 PAR signal regulation 
 
Activation of PAR1 by proteases is irreversible and thus termination of signaling is 
important to prevent uncontrolled signaling (Coughlin, 1999b; O'Brien et al., 2001).  
PAR1, like other classical GPCR, once activated is rapidly phosphorylated and internal- 
ized, but instead of recycling, activated PAR1 is sorted to lysosomes (Chen et al., 2004; 
Coughlin, 1999a; Trejo et al., 1998).  The desensitization of PAR1 signaling is regulated 
by multiple independent mechanisms including C-tail phosphorylation and binding of -
arrestins independent of phosphorylation (Chen et al., 2004).  Uncleaved PAR1 on the 
other hand, cycles constitutively between the cell surface and an intracellular compartment, 
by this, a protected receptor pool is generated (Arora et al., 2007).  This pool can 
repopulate the cell surface by receptors after proteases exposure independent of de novo 
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receptor synthesis (Arora et al., 2007; Coughlin, 1999a), thereby, rapid resensitization to 
proteases will be achieved (Arora et al., 2007; Coughlin, 1999a). 
 
1.7.1.3.1.4 PAR1 tissue distribution and function 
 
Since the discovery of RAR1, extensive research studies have identified it as an important 
player in different pathologic and physiologic situations.  PAR1 is the main thrombin 
receptor on vascular cells (Coughlin, 2005; Grand et al., 1996).  Its activation on the 
platelets' surface results in the change of platelets' shape, the release of Adenosine 
diphosphate (ADP) and thromboxane A2 (TxA2) (Coughlin, 2000).  PAR1 activation on 
endothelial cells results in the recruitment of immune cells, disruption of the endothelial 
cell barrier and migration and release of growth factors (Hirano and Kanaide, 2003).  
These functions suggest that PAR1 plays an important role in haemostasis, inflammation 
and vascular development (Coughlin, 2000; Traynelis and Trejo, 2007).  In vascular 
smooth muscle cells, PAR1 activation results in direct contractile effect mainly in 
atherosclerosis by mediating hypertrophy, proliferation, migration and production of 
extracellular matrix (Hirano and Kanaide, 2003; Martorell et al., 2008).  Hyperalgesia and 
edema as a result of neurogenic inflammation is PAR1 mediated (Coughlin, 2005).  It has 
been shown that PAR1 prevent apoptosis in neurons (Guo et al., 2004).  PAR1 has also 
been reported to be expressed on Hepatic stellate cells (Martinelli et al., 2008).   
 
Recent studies have advanced our knowledge about the important role that PAR1 plays in 
tumor development, metastasis and angiogenesis (Yin et al., 2003a; Yin et al., 2003b).  It 
has been reported that PAR1 is highly expressed in malignant tissue biopsy specimens and 
metastatic tumor cell lines (Even-Ram et al., 1998).  In normal epithelial tissue or cell lines 
of low metastatic properties, PAR1 showed little or no expression (Even-Ram et al., 1998; 
Grisaru-Granovsky et al., 2009).  The central role of PAR1 in tumors invasiveness and 
metastasis has been derived from different studies.  PAR1 plays an important role during 
metastatic breast carcinoma cell invasion and prostate cancer progression by enhancing 
both angiogenesis and tumor growth (Salah et al., 2005; Yin et al., 2003a).  Moreover, it 
has been noticed that PAR1 is exclusively expressed between the 7th- 10th weeks of 
gestation and completely shut off thereafter (undetectable by the 12th week) (Even-Ram et 
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al., 2003) suggesting a temporal and critical relationship between the expression of PAR-1 
and early placentation (Even-Ram et al., 2003; Grisaru-Granovsky et al., 2009).   
 
1.7.1.3.1.5 PAR1 in embryonic development 
 
It has been shown that 50% of Par1 Knockout mouse embryos die by E9-10 (Griffin et al., 
2001).  Death occurs as a result of multiple bleeding and cardiovascular failures suggesting 
that PAR1 and coagulation factors may contribute to normal blood vessel development 
(Griffin et al., 2001).  In the time period restricted for placentation, the expression of PAR1 
on CTB peaks in vivo between the 7th -10th weeks of gestation and totally shuts off later 
(Even-Ram et al., 2003).  This period coincides with the maximal invasion of CTB and the 
increased production of matrix metalloproteases and urokinase –type plasminogen 
activator (Cohen et al., 2006; Xu et al., 2000).  The pathobiology of some pregnancy 
disorders is related to dysregulation in CTB invasion (Even-Ram et al., 2003), for example, 
preeclampsia and restriction of fetal growth are related to shallow uterine invasion (Zhou 
et al., 1993), while partial and complete hydatidiform moles and choriocarcinoma are 
associated with extreme proliferation and invasion (Even-Ram et al., 2003; Yin et al., 
2003a). Consequently, PAR1 is crucial to many important processes involved in 
placentation and the over all of normal pregnancy. 
 
1.7.1.3.1.6 Polymorphisms in Par1  
 
Three different polymorphisms in human Par1 have been reported to have physiological 
significance (Arnaud et al., 2000; Dupont et al., 2003; Grisaru-Granovsky et al., 2007).  
The heavily studied, and the ones that found to have functional relevance include; an A/T 
single nucleotide polymorphism (SNP) in the 3′ end of the large intron near a putative 
splicing acceptor site (IVS-14 A/T) (rs168753) (Arnaud et al., 2000), a C/T transition at 
1426 upstream the translation start site (-1426 C/T) (rs32934) and a 13-base pair (bp) 
insertion repeat preceding -506 5′-CGGCCGCGGGAAG -3′ sequence (-506 I/D) 
(rs11267092) where I means insertion and D means deletion (Arnaud et al., 2000).  It has 
been shown that the polymorphism in IVS-14 A/T in the intron affects the density of PAR1 
receptors at the platelets surface; the presence of the T allele is associated with decreased 
expression (Dupont et al., 2003).  This suggest that IVS-14A/T SNP may be clinically 
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relevant in individuals who are at increasing risk of bleeding as mild hemophilia, surgical 
patients or von Willebrand disease (Dupont et al., 2003). 
 
It has been demonstrated that a 13bp I in the -506I/D polymorphism was under represented 
in male cases with venous thromboembolism (VTE) (Arnaud et al., 2000).  This result 
suggests a gender –dependent VTE protective effect of this insertion (Arnaud et al., 2000).  
It has been reported that the II genotype in -506 I/D polymorphism may be an essential 
predictive factor for esophageal adenocarcinoma (EA) and was associated with developing 
tumor recurrence (Lurje et al., 2010).  The -1426 C/T polymorphism, on the other hand, 
has been demonstrated to be implicated in chronic hepatitis C liver fibrosis, preterm 
delivery (PTD) and Gaucher disease.  Rate of Liver fibrosis (RF) has been reported to be 
faster in patients having the TT genotype compared with those having the CT or CC 
genotype (Martinelli et al., 2008).  Additionally, mothers heterozygous for this SNP were 
at risk concerning PTD (Grisaru-Granovsky et al., 2007).  Moreover, this SNP and its T 
allele have also been implicated with thrombocytopenia in Gaucher disease patients 
(Altarescu et al., 2010).  
 
1.7.1.3.1.7 Par1 Polymorphism detection methods 
 
Different PCR based mutation detection methods were used to detect PAR1 polymorph- 
ism.  For instance, Restriction Fragment Length Polymorphism (RFLP) was used to detect 
-506 I/D (Altarescu et al., 2010; Arnaud et al., 2000; Grisaru-Granovsky et al., 2007) and 
the -1426 C/T (Arnaud et al., 2000; Grisaru-Granovsky et al., 2007) polymorphism with 
the suitable restriction enzymes.  Others used size polymorphic PCR to detect -506 I/D 
(Dupont et al., 2003).  -1426 C/T polymorphism was detected by DNA sequencing 
(Altarescu et al., 2010; Dupont et al., 2003) or Amplification –Refractory Mutation System 
(ARMS) PCR (Martinelli et al., 2008).  In view of that, -1426 C/T polymorphism as other 
similar SNPs, can be detected by different PCR based SNP detection methods.  Even 
though, DNA sequencing is considered the gold standard technique, its high relative cost is 
the main disadvantage (Krypuy et al., 2006).  RFLP and ARMS on the other hand, is time 
consuming and expensive.  For that, we aim to assess the applicability of High resolution 
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melting (HRM) which is an application of Real-Time PCR (RT-PCR) in detecting this 
SNP.  
 
Melting curve analysis in conjunction with real-time PCR was introduced in 1997 
(Wittwer et al., 2003).  In one- tube, changes in florescence behavior can be monitored due 
to the release of an interchelating DNA dye from a DNA duplex as it is denaturated by 
increasing temperature (Krypuy et al., 2006).  Because different genetic sequences melt at 
slightly different rates, they can be viewed, compared, and detected using these curves.  
Our SNP of interest (-1426 C/T) is classified as class 1 SNP according to the duplexes that 
are produced after PCR amplification (Liew et al., 2004).  It can be simply recognized by 
melting analysis (Liew et al., 2004).  It has been reported that HRM analysis can detect 
mutations in clinical samples (Krypuy et al., 2006), and genotypes SNP as those for FVL, 
prothrombin and MTHFR (Liew et al., 2004). 
 
1.8 Literature review 
 
PAR1 and its association with human pregnancy is a new issue in which some studies were 
carried out, the results have highlighted the importance of temporal expression of PAR1 
and spatial regulation of PAR1 signaling for proper embryonic growth, migration, and 
development.  
 
A series of studies by Evan-Ram and colleagues have clearly shown that PAR1 is involved 
in restricted and unrestricted pathological trophoblast invasion (Even-Ram et al., 2003).  
Their studies showed that PAR1 is highly and spatially expressed between the 7th and 10th 
weeks of gestation in CTB and shut off after that (Even-Ram et al., 2003), moreover, they 
have shown that PAR1 is highly expressed in the CTB of completely hydatidiform mole 
(CHM) compared to very low expression in normal age-matched placenta (Even-Ram et 
al., 2003).  
 
A study by O’Loughlin et. al showed that vasodilation effect of thrombin in umbilical 
artery vasculature is PAR1 mediated, this finding is important for feto-placental circulation 
in normal pregnancy (O'Loughlin et al., 2005).  Adverse pregnancy outcome such as 
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preeclampsia (PE) and intrauterine growth retardation may be related to non-thrombotic 
effect of thrombin through PAR1 (O'Loughlin et al., 2005). 
 
A pilot case-control study performed by Grisaru-Granovsky et.al proved an association 
between Par1 polymorphism (-506 I/D, -1426C/T and -14 IVS A/T) and unfavorable 
pregnancy outcome.  Polymorphisms in the 5′ regulatory region and intervening sequence 
were investigated in PE, preterm delivery (PTD) and small for gestational age babies 
(SGA).  This study showed that there is an association between maternal heterozygous 
allele of the -1426 C/T polymorphism of Par1 and PTD (Grisaru-Granovsky et al., 2007) 
and did not show an association between neonatal Par1 polymorphism and adverse 
pregnancy outcome (Grisaru-Granovsky et al., 2007). 
 
In a cross-sectional study, Erez et. al. demonstrated a strong PAR1 expression in placentas 
from preterm PE complicated pregnancies compared with placentas from spontaneous 
preterm labor (Erez et al., 2008). 
 
Another recent study carried by Grisaru-Granovsky and colleagues has demonstrated for 
the first time the causal association between PAR1 and catenin stabilization in placental 
CTB.  They showed that silencing of Par1 significantly inhibits proliferation and invasion 
of CTB (Grisaru-Granovsky et al., 2009). 
 
A case control study by Arnaud and coworkers was carried out to find an association 
between PAR1 polymorphism and VTE.  While genotypes and allele frequencies of the     
-506 I/D, -1426 C/T and the IVs -14 A/T were similar between cases and controls, the 
allele I was under represented in male cases with VTE.  This suggests a possible gender-
dependent protective effect of the insertion in males (Arnaud et al., 2000). 
 
A study by Dupont and colleagues was carried out to examine the effect of Par1 
polymorphism on the expression and function of PAR1 on platelet surface. While the - 506 
I/D and the -1426 C/T were not associated with the platelets PAR1 phenotype, the IVs -14 
A/T was associated with PAR1 expression level.  Carriers for the homozygous A allele had 
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a significantly higher PAR1 level than heterozygous carriers, and the presence of the T 
allele showed a decreased platelets response to SFLLRN (Dupont et al., 2003). 
 
Martinelli et. al. in their study showed a relationship between the TT polymorphism in the 
-1426 C/T polymorphism and the rate of liver fibrosis.  Patients homozygous for the T 
allele showed higher RF compared with heterozygous (CT) or homozygous for the C 
allele.  However, the IVS -14 A/T and the - 506 I/D showed no difference on RF among 
the different genotypes (Martinelli et al., 2008).  
 
Recently, a study carried out by Altarescu et. al. aimed to describe Par1 polymorphism in 
Gaucher disease.  The prevalence of -1426 C/T SNP with the TT genotype were found to 
be statistically significant among Gaucher disease patients compared to controls.  Although 
this SNP was not found to be associated with disease severity, need for enzyme 
replacement therapy or splenectomy, it was associated with low platelets’ count.  On the 
other hand, homozygous -506 I/D polymorphism with the II genotype was found to be 
correlated with lower bone mineral density at the femoral neck area compared with 
patients having other genotypes (Altarescu et al., 2010). 
 
Lurje et. al. in their study concerning EA and genetic variations in angiogenesis related 
pathways showed that -506 I/D polymorphism with the II genotype may be an important 
prognostic factor for EA.  The II genotype was significantly related to tumor recurrence.  
This polymorphism may increase the angiogenic potential that is vital for the development 
of EA tumor progression (Lurje et al., 2010). 
 
To the best of our knowledge, no data on the association between Par1 gene 
polymorphism and RA is available so far.  
 
 
 
21 
 
 
 
 
 
 
 
Chapter Two  
 
 
Methodology 
 
2.1 Sampling  
 
2.1.1 Inclusion criteria 
 
Samples from Palestinian females in child bearing age suffering from RA (two or more 
consecutive spontaneous abortion) in the first trimester matched with females with two or 
more normal deliveries were analyzed for polymorphisms in the 5′regulatory region of 
Par1.  All women were provided with a written informed consent prior to the collection of 
blood samples.  This research was performed in accordance with the declaration of 
Helsinki used by the Palestinian Ministry of health.  
 
2.1.2 DNA Controls 
 
Previously genotyped samples by DNA sequencing for each polymorphism were used as 
DNA control in this study. 
 
2.1.3 Research place 
 
The research was carried out at Al-Quds Nutrition and Health Research Institute 
(ANAHRI), Al –Quds University, Abu Dies. 
 
2.2 Sample processing:  
 
2.2.1 Blood sample collection 
 
Blood samples were collected from participants for DNA extraction as whole blood in 
EDTA tubes (5ml).  The samples were stored at 4 0C up to three days. 
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The samples were collected from: 
 Primary Health Care Center/ Ramallah. 
 NGOs (Red Crescent Hospital/ Jerusalem).  
 Private Centers. 
 
2.2.2 Genomic DNA extraction 
 
DNA extraction was done using MasterPureTM (according to the manufacturer’s 
instruction) DNA Purification Kit for Blood (Epicentre Biotechnology, Madison, USA).  
DNA quantity and quality were measured using Nanodrop 1000 spectrophotometer 
(Thermo Scientific, Bancroft, USA), soft copy version (3.7.1).  The following parameters 
were obtained; DNA concentration, the 260/230 ratio (for any DNA contamination by 
phenolate ion, thiocyanates since both solvents used in DNA extraction procedure) and the 
260/ 280 ratio to evaluate nucleic acid contamination by protein.  DNA was then stored at   
-20 0C until used. 
 
2.3 Polymorphisms identification 
 
2.3.1 Size polymorphic PCR 
 
This technique was used to test for -506 I/D (rs11267092) polymorphism.  PCR primers 
were designed according to (http://frodo.wi.mit.edu/primer3/) to give PCR products of 100 
and 113bp for the deletion (D) and insertion (I) alleles, respectively.  The primer sequences 
are shown in table (2.1).  Their location on Par1 gene is shown in figure (2.1).  PCR 
amplification was performed using PCR-Ready TM High Yield Kit (Syntezza Bioscience, 
Jerusalem).  To each tube a mixture of 22.5 l distilled water (DEPC treated, Beit Haemek, 
Israel), from each primer (Rmut30 and Del13Ins), 0.5l (0.5 uM) (Syntezza Bioscience, 
Jerusalem), 0.5 l formamide (Promega, Madison, USA) and 1l (100 ng/l) DNA were 
added.  Formamide was added to enhance PCR specificity.  PCR amplification was done 
on preheated Gene Amp PCR system 9700 (PE Applied Biosystem) according to the 
following conditions:  initial denaturation at 95 0C for 3 minutes followed by 35 cycles of 
denaturation at 95 0C for 30 seconds, annealing at 55 0C for 30 seconds, extension at 72 0C 
for 40 seconds and final extension at 72 0C for 7 minutes.  The products were analyzed 
using 3% agarose gel (Sea-KemR LE agarose, lonza, USA), and visualized by Image 
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Master VDS (Pharmacia Biotech) and documented using Fujifilm, thermal imaging system 
FTI-500.  Previously sequenced DNA samples were used as controls.  Moreover, twenty 
percent of the samples were repeated randomly.  The products were evaluated according to 
the following criteria:  The homozygous insertion allele (II) was one band with 113bp in 
length.  The heterozygous allele (ID) was two bands, 113bp and 100bp in length.  On the 
other hand, the homozygous deletion allele (DD) was one band with 100 bp.  
 
2.3.2 Restriction Fragment Length Polymorphism (RFLP) 
 
This technique was used for the -1426 C/T (rs32934) polymorphism detection.  This 
method was proposed to be done according to Arnaud et al.(Arnaud et al., 2000), however, 
the restriction criteria were totally different when compared with the Nebcutter.  While the 
C allele was sited to remain uncut and the T allele was sited to lose 39 bp, the Nebcutter 
revealed a totally different digestion criterion.  According to the Nedcutter, both alleles 
will lose 15 bp and the C allele will also lose another 25 bp, consequently the difference 
between the two alleles was only 25 bp (418 / 393 bp) but not 39 bp (433/ 393 bp) as sited 
in the article.  This difference between the two alleles was difficult to detect, for that, 
modifications were performed. 
 
2.3.2.1 RFLP modification  
 
Newly designed Primers were performed to allow proper detection of this SNP.  This 
modification was performed in order to obtain shorter PCR product to get better resolution 
and to see if there is another suitable restriction enzyme.  Two sets of PCR primers were 
designed according (http://frodo.wi.mit.edu/primer3/) to give PCR products of 223 bp or 
293 bp before digestion.  The reverse primer was used according to Arnaud et. al. (Arnaud 
et al., 2000), and newly designed one was used that allow digestion by another restriction 
enzyme.  The restriction enzyme was chosen according to NEBcutter V2.0 (http://tools.- 
neb.com/NEBcutter2/).  The primer sequences with the suitable restriction enzyme used 
for the modification are shown in table (2.2) and their locations on our gene are shown in 
figure (2.1).  PCR was done as mentioned above without formamide addition.  PCR 
amplification was done on Mastercycler gradient PCR machine (Eppendrof, North 
America, USA) according to the following conditions: initial denaturation at 96 0C for5 
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minutes followed by 38 cycles of denaturation at 95 0C for 30 seconds, extension at 72 0C 
for 50 seconds and final extension at 72 0C for 6 minutes.  We tested annealing at 58 0C, 60 
0C, and 62 0C for 30 seconds.  The PCR products were analyzed on 1.5% agarose (Sea- 
KemR LE agarose, lonza, USA).  According to the analyzed product we decided to 
continue our optimization and work with the shorter PCR products.  
After amplification using our newly designed primers and optimized annealing 
temperature, digestion of PCR products was performed according to the following 
protocol: 20l PCR product, 1l of the corresponding restriction enzyme, HpaII or BstN1 
(Fermentas, Burlington, Canada), 2.5l of 10X of the corresponding buffer with BSA 
(Fermentas, Burlington, Canada).  PCR products were digested for 2 hours at 370C and 
then analyzed on 3% agarose gel (Sea-KemR LE agarose, lonza, USA).  PCR products were 
visualized and documented as stated above.  The products were evaluated according to the 
criteria clarified in tables (2.3-2.4) using the NEB cutter web site V2.0 (http://tools.neb.-
com/NEBcutter2/). 
 
After optimization, we decided to work with the primers that gave a PCR product of 223bp 
and digested with HpaII restriction enzyme.  Furthermore, 10% of the samples were 
repeated randomly with the primers that gave PCR product of 223 bp and digested with 
BstN1 enzyme as a confirmatory step. 
 
2.3.3 DNA sequencing   
 
For quality assurance purposes, direct DNA-sequencing was performed to confirm validity 
of the methods used.  These samples were used as a positive control in HRM genotyping 
technique. 
 
2.3.3.1 PCR product cleaning  
 
Before sequencing, PCR products were purified using High pure PCR product purification 
Kit (Roche, Germany) according to the manufacturer’s instruction.  Samples were then 
sequenced from both directions (5′ and 3′) with FCTPara-sh forward primer (10 uM) and 
HpaIICTR reverse primer (10 uM).  
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2.3.4 Real Time-PCR (RT-PCR) and HRM 
 
2.3.4.1 RT-PCR preparation  
 
It has been noted that shorter amplicon in HRM is more sensitive in detecting mutation 
than larger one (Krypuy et al., 2006).  Therefore, primers with 76 bp product to detect the 
C/T mutation were designed using (http://frodo.wi.mit.edu/primer3/) web site.  The primer 
sequences are shown in table (2.1) and their locations on our gene are shown in figure 
(2.1). PCR amplification was performed in a 20 l reaction volume.  To each tube a 
mixture of 3.4 l distilled water, 4l primer mix (10 pM), 10 l of hot start PCR master 
mix (X2) (Thermo Scientific, Bancroft, USA), 0.6 L SYTO9 (1.5mM) (Invitrogen, 
Carlsbad, CA, USA), 2l DNA (100- 200 ng/reaction).  PCR cycling and HRM analysis 
were carried out using Rotor-Gene 6000 (Corbett Research, New South Whale, Australia) 
and its software version 1.2 according to the following conditions: after an initial 
denaturation at 95 0C for10 minutes, 40 cycles were carried out; 95 0C for 5 seconds, 60 0C 
for 10 seconds, 72 0C for 20 seconds and melting from 75 - 95 0C rising at 0.2 0C per 
second.  
 
To make sure that the amplified product matched with the estimated size, PCR products 
were analyzed by gel electrophoresis.  PCR products were visualized and documented as 
stated above.  To every run negative and positive controls were included.  All PCR 
reactions were performed in duplicates.  
 
2.3.4.2 Melting curve analysis 
 
Melting curve analysis was performed directly on the same instrument after amplification 
with its provided software.  Different curves were obtained and all of them aimed to 
discriminate between different genotypes.  Derivative melting curves were obtained for 
direct comparison after melting.  In theses curves the fluorescence signal is plotted against 
the temperature, as the double stranded DNA becomes single stranded, the fluorescence 
intensity decreases and the dye is released.  The melting temperature (Tm) at which 50% of 
the DNA is double stranded can be obtained from them (Erali et al., 2008).  Normalized 
curves were another design for analysis.  In these curves, linear baselines before and after 
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melting transition were defined for each sample.  Then fluorescence intensity was 
normalized between 0% and 100%.  Fluorescence acquisition at each temperature was 
calculated as the percentage of fluorescence between the top and the bottom baselines for 
each sample (Wittwer et al., 2003).  The melting profile was also demonstrated as 
difference plots, in which the melting curve for one C/T sample (that was further 
confirmed by sequencing) was chosen as a reference and became a horizontal line at zero 
as it is subtracted from itself.  The difference between each curve and the reference was 
plotted against temperature.  These plots allow different genotypes to cluster in groups for 
easier visual inspection (Wittwer et al., 2003). 
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Table 2.1: PCR primers used in Par1 polymorphism analysis. 
 
SNP site and 
method of 
detection 
Sequence 5′- 3′ Primer direction 
-506 I/D 
Size 
polymorphic 
CACTGTGGACGTCTCCACAT Forward (Del 13 Ins)
GCGAAGCTGTCAGTGA Reverse (R mut 30) 
-1426 C/T 
RFLP 
GCTGCAGCTTATCAACCACA Forward  
FCT Para-sh 
TGCTAAGGGCCCCCAGGGGCGTCG 
CGGCTGGGGGTGGGCG 
Reverse 
(HpaIICTR) 
-1426 C/T 
HRM 
ACTTAAGCTGCAGGCTCCTC forward HRMCT 
PAR1 
ACACTCGCTTGGCAGTCTG Reverse (PCR2 CT) 
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     Table 2.2: PCR primers used in RFLP modification. 
 
Primer 5′-3′ Sequence 5′-3′ Band size Restriction 
enzyme  
Forward 
HpaIICTR 
TGGGGGAATGATACTCTTCG 
 
293 
 
BstN1 Reverse 
TR2Lmod 
TGCTAAGGGCCCCCAGGGGCGTC 
GCGGCTGGGGGTGGCC 
Forward 
FCT Para-sh 
GCTGCAGCTTATCAACCACA 
 
223 
 
BstN1 Reverse 
TR2Lmod 
TGCTAAGGGCCCCCAGGGGCGTCG 
CGGCTGGGGGTGGCC 
Forward 
HpaIICTR 
TGGGGGAATGATACTCTTCG 
 
293 
 
HpaII Reverse 
HpaIICTR 
TGCTAAGGGCCCCCAGGGGCGTC 
GCGGCTGGGGGTGGGCG 
Forward 
FCT Para-sh 
GCTGCAGCTTATCAACCACA 
 
223 
 
HpaII Reverse 
HpaIICTR 
TGCTAAGGGCCCCCAGGGGCGTC 
GCGGCTGGGGGTGGGCG 
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2.3.5 Agarose Gel Preparation and Electrophoresis 
 
The 4, 3, 1.5 % agarose gel was prepared by dissolving 4, 3, 1.5 grams agarose (Sea Kem R 
LE agarose, Lonza, USA) respectively in 100 ml 1X TAE electrophoresis buffer (0.04 M 
Tris –Acetate, pH 8.0 and 0.001 M EDTA), boiled in microwave, and when it cooled to 
about 50oC, 5l of ethidium bromide (0.5 ug/ml) (Sigma) was added.  
 
The PCR products were analyzed on horizontal gel electrophoresis SUB- Cell R GT (Medi 
Pharm, Beit-Sahour). The applied voltage was 120 volt in the first 10 min then at 100 volt 
for 1 hour.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3: The virtual product size after digestion according to Neb cutter 
for the C allele. 
 
PCR length 
(bp) 
Enzyme Ends Coordinates Bands size 
(bp) 
293 
BstN1 (LeftEnd)-BstNI 1-253 253 
BstNI-BstNI 254 -278 25 
BstNI-(RightEnd) 279 -293 15 
293 
HpaII HpaII-HpaII 62 -252 191 
(LeftEnd)-HpaII 1 -61 61 
HpaII-(RightEnd) 253 -293 41 
223 
BstN1 (LeftEnd)-BstNI 1 -183 183 
BstNI-BstNI 184 -208 25 
BstN1(RightEnd) 209 -223 15 
223 
HpaII (LeftEnd)-HpaII 1-182 182 
HpaII-(RightEnd) 183 -223 41 
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Table 2.4: The virtual product size after digestion according to Neb cutter 
for the T allele.  
PCR 
length(bp) 
Enzyme Ends Coordinates Bands size (bp)
293 BstN1 
(LeftEnd)-BstN1 1-278 278 
BstN1-(RightEnd) 279-293 15 
293 HpaII 
(LeftEnd)-HpaII 1-61 61 
HpaII-(RightEnd) 62-293 232 
223 BstN1 
(LeftEnd)-BstNI 1-208 208 
BstNI-(RightEnd) 209-223 15 
223 HpaII LeftEnd- 
RightEnd
Uncut 223 
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Figure 2.1:  Human Par1 gene, exon 1 and partial cds (accession no. AF054633.1.). Red 
primers are for the -1426 C/T SNP with the HRM.  The green primers are for the -506 I/D 
primers.  The blue primers are for the -1426 C/T SNP with RFLP, the grey nucleotide A 
was shared between the RFLP and HRM primers.  The C nucleotide is the site of the SNP, 
The T near the site of SNP was changed in the reverse primer to G in order to be cut with 
HpaII enzyme.  The C near the site of SNP, it was changed to G in the reverse primer in 
order to be cut with BstN1 enzyme.  CGGCCGCGGGAAG is the site where insertion takes 
place in the -506 site. 
 
2.4  Statistical analysis 
 
The association between different genotype in females with recurrent abortion and those 
with normal pregnancies was done using Pearson Chi-square or fisher exact whenever 
appropriate.  A p-value of < 0.05 was considered statistically significant.  The analysis was 
performed using SPSS V17.0.  Allele frequencies were calculated manually.  Distribution 
of the alleles was tested for departure from Hardy-Weinberg equilibrium (HWE) using the 
(http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl) website.  The allele frequencies 
were observed within the probability limits (P < 0.05, for HWE) using Pearson Chi-square 
or fisher exact whenever appropriate.  
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Chapter Three 
 
 
Results 
 
3.1 Population Study  
 
This study was performed to find out the association between polymorphism in Par 1 
gene and recurrent abortion.  To achieve our goal, we have genotyped Palestinian 
females for Par1 polymorphism in the 5′ regulatory region, namely -1426C/T (rs32934) 
SNP and -506 I/D (rs 11267092) polymorphism.  A total of 415 participants were 
evaluated for the -506 I/D polymorphism consisting of 174 (41.9%) cases and 241 
(58.1%) controls.  230 participants were evaluated for the –1426 C/T polymorphism, 
consisting of 122 (53%) cases and 108 (47%) controls.  For the -506 I/D polymorphism 
detection , the case  group was women who had two (43.8%) or more (56.2%) 
consecutive first trimester miscarriage (figure 3.1a,) with a mean age (32.82 years) as 
shown in Table 3.1.  For the -1426 C/T polymorphism, the case group was women who 
had two (24.5%) or more (75.5 %) consecutive first trimester miscarriage (figure 3.1 b) 
with mean age (32.89 years) as shown in Table (3.1).  The control group for both 
polymorphisms was women who had two or more successful pregnancy outcome with 
mean age 28.53 years for -506 I/D and 27.96 years for -1426 C/T ( Table 3.1).  Our 
study subjects belonged to the same ethnic group.  They were distributed among the 
north and center area of Palestine.  For the -506 I/D, 77.8% of participants were from 
the north and 22.2% were from the center (figures 3.2 a).  For the -1426 C/T, 64.3% of 
the participants were from the north and 35.7% of the participants were from the center 
(figure 3.2 b).  Any case suffered from second or third trimester pregnancy loss was 
excluded from the study.  The cases did not exclude for other abnormalities or mutations 
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except in cases from the center area of Palestine because the cost of the study will be 
highly elevated. 
 
(a) 
 
 (b) 
 
Figure 3.1: Distribution of cases (%) by number of abortions.  a) -506 I/D polymorphism 
participants (cases, n = 174). B) -1426 C/T SNP participants (cases, n= 122). 
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(a) 
 
 
(b) 
 
Figure 3.2:  Distribution of participants (%) among the north and center area of Palestine.  
a) Participants in -506 I/D polymorphism genotyping.  b) Participants in -1426C/T 
polymorphism genotyping. 
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Table 3.1:  Distribution of participants by age. 
 
Polymorphism Mean age of cases Mean age of controls  
-506 I/D 32.82 ± 6.6 8 28.53 ± 5.84 
-1426 C/T 32.89 ± 6.78 27.96 ± 6.03 
Mean (years) ± SD. 
 
3.2 Genotyping results. 
  
3.2.1  Screening for the -506 I/D (11267092) by size polymorphic PCR  
 
In order to genotype the -506I/D polymorphism we used size polymorphic PCR.  This 
technique unlike the previously used RFLP technique (Altarescu et al., 2010; Arnaud et al., 
2000; Grisaru-Granovsky et al., 2007) or Dynamic Allele Specific Hybridization (DASH) 
was easy and rapid.  In this technique the DD, ID, and II genotypes give PCR products of 
100, 100 and 113, respectively as clearly seen in figure (3.3).  We tested our technique 
validity by genotyping previously sequenced samples and found it valid in all the cases.  
 
 
Figure 3.3:  -506 I/D polymorphism genotyping by size polymorphic PCR.  Lane 1 
represents Hinf l digest DNA ladder.  Lane 2, negative control.  Lanes (3, 5, 7-10, 12) 
show DD genotype with 100 bp.  Lanes (4, 6, 11,15) show ID genotype with 113/100 and 
lanes (13, 14, 16) show II genotype with 113bp. 
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3.2.2 Screening for the -1426 C/T ( rs32934) SNP by RFLP 
 
Different techniques were used to detect this SNP; RFLP (Arnaud et al., 2000; Grisaru-
Granovsky et al., 2007), DNA sequencing (Altarescu et al., 2010; Dupont et al., 2003) and 
Amplification –Refractory Mutation System (ARMS) PCR (Martinelli et al., 2008).  We 
have chosen to detect this SNP by RFLP according to Arnaud et. al. (Arnaud et al., 2000), 
because the difference between the two alleles were only 25 bp (418 / 393 bp) and not 39 
bp as sited in the article (433/ 393 bp) we modified this method.  For this modification, 
different pairs of primers that can be cut by different restriction enzymes (HpaII and 
BstN1) were used.  Optimization for the PCR was done using different annealing 
temperatures with the selected pairs of primers (figure 3.4).  The 600C annealing 
temperature – second group - has the minimal nonspecific bandings with the pairs of 
primers that gave PCR products of 223 bp and can be cut by BstN1 and HpaII enzyme. 
 
 
 
Figure 3.4: RFLP optimization using different sets of primers combinations and different 
annealing temperature.  Lane 1 represents the 50bp DNA ladder.  Each group is composed 
of PCR products that can be cut by BstN1, short (223bp), long (293) and by HpaII short 
(223bp), long (293bp), respectively.  Annealing temperature was 58, 60,and 62 0C, for 
each group respectively. 
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After optimization, we decided to work with the primer pairs that gave products size of 
223bp before restriction as shown in figure 3.5.  Although our modified RFLP method was 
able to differentiate CC genotype from the CT genotype with both enzymes, the HpaII 
enzyme gave better resolution, as shown in figure 3.6.  Ten percent (10%) of the samples 
were repeated randomly with BstN1 enzyme to confirm the results (figure 3.7).  The TT 
genotype was absent among our participants.  As seen in figure (3.5, 3.6, 3.7), the 
theoretically calculated band sizes agreed with the ones appeared in the gel.  The results 
obtained with our modified RFLP method were confirmed by DNA sequencing. 
 
 
 
Figure 3.5:  PCR products for the -1426 C/T before digestion.  Lane 1 represents the 50 bp 
DNA ladder.  Lane 2 is the negative control.  The rest of lanes represent the PCR products 
before restriction with 223bp band size. 
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Figure 3.6: -1426 C/T SNP genotyping by RFLP with HpaII enzyme.  Lane 1 represents 
the 50 bp DNA ladder; Lane 2 is the negative control, lanes (3-5) show CT genotype with 
223/182 bp bands , lanes (6-9) show CC genotype with 182 bp band and lane 10 shows the 
uncut products with 223 bp band size. 
 
 
 
 
Figure 3.7:  -1426 C/T SNP genotyping by RFLP with BstN1 enzyme.  Lane 1 represents 
the 50 bp DNA ladder; Lane 2 is the negative control, lanes (3-9,12) show CC genotype 
with 183 bp band, and lane (10) shows the uncut products with 223bp band , lane (11) 
shows CT genotype with 208/183 bp bands size. 
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3.2.3 DNA sequencing 
 
DNA sequencing was used for genotyping -1426 C/T SNP for quality assurance purposes.  
The results of the RFLP matched with the results of sequencing.  Figure (3.8), represents 
the chromatogram of the CC genotype with one peak for the C nucleotide at the -1426 site.  
In contrast, T and C peaks are seen at the -1426 site with CT genotype (figure 3.9). 
 
 
 
Figure 3.8:  -1426 C/T SNP genotyping by DNA sequencing.  The chromatogram shows 
the C nucleotide peak in CC genotype.   
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Figure 3.9:  -1426 C/T SNP genotyping by DNA sequencing.  The chromatogram shows 
both C and T nucleotide peaks in CT genotype.   
 
3.2.4 Real Time-PCR and HRM 
 
In this study, we aimed to assess the applicability of HRM methodology in detecting -1426 
C/T.  For this purpose, samples tested by RFLP and DNA sequencing were used as 
controls for the HRM.  By HRM the CC can be clearly distinguished from CT genotypes in 
a simple, rapid manner.  Different graphs were used to evaluate genotype as shown in 
figure (3.10, 3.11, 3.12).  Different genotypes can be easily discriminated by normalized 
(figure 3.11) and fluorescence difference (figure 3.12) curves in these curves each 
genotype tends to be in one cluster.  Each genotype has different melting behavior as 
clearly seen in derivative melting curve (figure 3.10), this figure also reflect the stability of 
the CC genotype.  For quality assurance, HRM PCR products were analyzed by gel 
electrophoresis and the obtained bands (78bp) matched with expected band size as shown 
in figure (3.13). 
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Figure 3.10:  Derivative melting curve for Par 1 (-1426 C/T) SNP.  PCR products with CT 
genotype show two melting peaks, while the CC genotype shows only one peak.  
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Figure 3.11: Normalized HRM curves for -1426 C/T SNP genotyping.  Samples with the 
same genotype tend to be in one cluster.  
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Figure3.12:  Fluorescence difference curves.  Difference in fluorescence compared to one 
of the heterozygous samples (C/T), curves were plotted against the temperature, leading to 
clear separation of sample groups with the same genotype (ref: reference sample).  
 
 
 
Figure 3.13:  HRM PCR products for the -1426 C/T SNP. Lane 1 represents is the 100 bp 
DNA ladder, lane (2- 7) are HRM products with 78bp size. 
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3.3  Distribution of Par1 genotyping among Palestinian females 
 
We have genotyped females for PAR1 polymorphism in the 5′ regulatory region, namely   
-506 I/D (rs11267092) and -1426 C/T (rs32934).  As shown in figure (3. 14), the DD was 
present in 48.3% among cases and 41.9% among controls.  The ID genotype was present in 
37.9% among cases and 41.1% among controls while the II genotype was present in 13.8% 
in cases and 17.0% in controls. For the -1426 C/T SNP only two genotypes were present 
since the TT genotype is not detected in our participants.  As shown in figure (3.15), the 
CC genotype was present in 97.5% in cases and 98.1% in controls.  The CT genotype was 
present in 2.5 % among cases and 1.9% among controls.  The distribution of - 506 I/D and 
-1426 C/T genotypes of Par1 polymorphisms and minor allele frequencies is described in 
table (3.2, 3.3) respectively. The polymorphisms inspected in this study showed no 
deviation from Hardy – Weinberg equilibrium (HWE).  The prevalence of -506 I allele was 
51.7% and 58.1 % of cases and controls, respectively and -1426 T allele was 2.5% and 
1.9% of cases and controls, respectively.  The prevalence of these two alleles was not 
significantly different between the two groups.  Table (3.4) represents the allelic odds ratio 
with the 95% confidence interval.   
 
Patients with known abnormalities were only excluded from the center area of Palestine, 
for that, the genotyping results were further analyzed according to their distribution (the 
north and the center area of Palestine).  Table 3.5 and 3.6 represent the distribution of - 506 
I/D and -1426 C/T genotypes of Par1 polymorphisms and minor allele frequencies.  
According to the center area of Palestine, the prevalence of -506 I allele at the center was 
48.1 % and 42.1 % of cases and controls, respectively and -1426 T allele was 4.3 % and 
2.9% of cases and controls, respectively.  The prevalence of these two alleles was not 
significantly different between the two groups.  Table (3.4) represents the allelic odds ratio 
with the 95% confidence interval.   
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Figure 3.14:  Distribution of -506 I/D Polymorphism among Cases and Controls.  No 
significant association between different genotypes and the two groups (p= 0.399). 
 
 
 
Figure 3.15:  Distribution of -1426 C/T SNP among Cases and Controls.  No significant 
association between different genotypes and the two groups (p=1.0). 
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Table: 3.2 Genotype and Minor Allele Frequencies for the -506 I/D Polymorphisms in 
Cases and Controls. 
 
Genotype  Cases, n (%) Controls, n (%) 
DD 84 (48.3 ) 101 (41.9) 
ID 66 (37.9 ) 99 (41.1) 
II 24 (13.8 %) 41 (17.0)  
Total  174 241  
Allele I frequency 0.328 0.376 
P = 0.399a 
a: Chi square test.  n: number 
 
Table 3.3: Genotype and Minor Allele Frequencies for the -1426 C/T SNP in Cases and 
Controls. 
 
Genotype Cases, n (%) Controls, n (%) 
CC 119 (97.5) 106 (98.1) 
CT 3 (2.5) 2  (1.9) 
TT 0 (0) 0 (0) 
Total  122   108 
Allele T frequency 0.012 0.009 
P =1.0 (F)a 
a: Fisher Exact Test.  n: number   
 
 
Table 3.4:  Allelic odds ratio for Par1 polymorphism. 
 
polymorphism OR  95% CI   P Value  
-506 I/D 0.8 0.6 - 1.1 0.155 (P)a 
-1426 C/T 1.3 0.2 - 8.0 1.0 (F)b 
-506 I/D (center) 1.2 0.6 – 2.2 0.668 P)a 
-1426 C/T (center) 1.5 0.1 – 16.9 1.0 (F)b 
a:Chi square test . b :Fisher Exact Test. CI : Confidence Interval.  OR: odds ratio 
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Table 3.5: Genotype and Minor Allele Frequencies for the -506 I/D Polymorphism in 
Cases and Controls according to their distribution. 
 
   Center of Palestine, n (%)  
 
The North of Palestine, n (%)  
Genotype  Cases  Controls) Cases  Controls  
DD 28 (51.9) 22 (57.9) 56  (46.6) 79 (38.9) 
ID 19 (35.2) 11 (28.9) 47 (39.2) 88 (43.4) 
II 7 (12.9) 5 (13.2) 17 (14.2) 36 (17.7) 
Total  54 38 120 203 
Allele I 
frequency 
0.306 0.276 0.338 0.394 
 P = 0.812a P = 0.371a
a: Chi square test.  n: number. 
 
Table 3.6:  Genotype and Minor Allele Frequencies for the -1426 C/ T SNP in Cases and 
Controls according to their distribution.  
 
   Center of Palestine, n (%)  
 
The North of Palestine, n (%)  
Genotype  Cases  Controls) Cases  Controls  
CC 45 (95.7) 34 (97.1) 74 (98.7) 72 (98.6) 
CT 2 (4.3) 1 (2.9) 1 (1.3) 1 (1.4) 
TT 0 (0) 0 (0) 0 (0) 0 (0) 
Total  47 35 75 73 
Allele T 
frequency 
0.021 0.014 0.007 0.007 
 P = 1 (F)a P = 1 (F)a 
a: Fisher Exact Test.  n: number   
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Chapter Four 
 
 
4.1 Discussion  
 
Even though different causes of RA are known to date, the cause in half of the cases are still 
unknown (Allison and Schust, 2009).  Hence, RA is an annoying condition for physicians 
and upsetting for patients.  For that, more efforts should be done on the way to identify 
further risk factors to find an appropriate treatment and prevent over treatment of an 
enormous number of women who receive either heparin or hormonal treatment as prophyla- 
ctic protocols to prevent RA (Dudding and Attia, 2004; Horne and Alexander, 2005). 
 
In order to solve such a problem, it is mandatory to know the pathophysiology of 
pregnancy in the different trimesters.  One of the important aspects of pregnancy in the 
first trimester is the implantation of the blastocyst and placental formation (Cross et al., 
1994; Damsky and Fisher, 1998).  During this process, CTBs proliferate, become motile 
and invade the maternal uterus (Cross et al., 1994).  Although little is known at the 
molecular level concerning implantation (Flamigni et al., 1991; Inagaki et al., 2003), the 
over expression of PAR1at the time restricted to the invasion period (between the 7th to 
10th weeks of gestation ) is well documented (Even-Ram et al., 2003).  For that, we 
hypothesized that -506 I/D and -1426 C/T polymorphisms in Par1 might alters the 
expression of this gene and increases the risk of RA.  
 
To reach our goal, a case –controlled study was performed among participants from the 
same ethnic group.  While the case was females suffered from two or more consecutive 
pregnancy loss in the first trimester of pregnancy, the control was females who gave birth 
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normally for two or more babies.  Those participants were genotyped for 
Par1polymorphisms in the 5′regulatory region that affect gene expression, namely -1426 
C/T (rs32934) and - 506I/D (rs11267092) polymorphisms.  There was no statistically 
significant difference between the two groups in the two examined polymorphisms.  PCR 
based detection methods were used successfully for genotyping purposes.  Moreover, the 
applicability of HRM was examined for the -1426 C/T SNP genotyping.  This method 
successfully differentiates different genotypes and can be considered as a cost effective, 
rapid technique for detecting and screening this SNP.  
 
The -506 I/D polymorphism was genotyped using size polymorphic PCR technique.  Our 
designed primers were able to detect the different genotypes (DD, ID and II) (figure 3.3) 
effectively and the results obtained by this method matched well with previously DNA 
sequenced samples.  Unlike RFLP -the most used method detect this polymorphism 
(Altarescu et al., 2010; Arnaud et al., 2000; Grisaru-Granovsky et al., 2007) or Dynamic 
Allele Specific Hybridization (DASH) (Gigante et al., 2009), our method can detect the 
different genotypes in one step PCR without restriction enzymes or labeled probes, which 
lowers the cost and reduces time required to test this polymorphism.  This method was also 
used by Dupont et. al. with different sets of primers (Dupont et al., 2003).   
 
The -1426 C/T SNP was genotyped using RFLP technique.  We planned to work according 
to Arnaud et. al. (Arnaud et al., 2000), however, we faced difficulties in detecting the 
different genotypes (CT and CC) despite the long time given for the PCR products to be 
separate on agarose gel electrophoresis.  Moreover, Altarescu et. al. and coworkers did not 
work according to Arnaud et. al. for technical reasons too, and DNA sequencing was used 
instead (Altarescu et al., 2010).  We successfully solved this problem with our newly 
designed primers and their corresponding restriction enzymes.  Our modified method gave 
better resolution for the different genotypes (CC and CT) (figure 3.6, 3.7) and the results 
obtained with it matched well when further confirmed by sequencing (figure 3.8, 3.9).  
 
Different PCR based SNP detection methods were used to detect -1426 SNP and similar 
SNPs.  RFLP is a simple method, can be performed at every standard laboratory that has a 
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thermal cycler and electrophoresis system and can be considered as a reliable method.  
Nevertheless, it is labor, expensive and time consuming because of post-PCR manipua- 
tion.  ARMS although do not require post PCR manipulation, the need of two separate 
PCR reactions is also expensive and time consuming (Ye et al., 2001).  DNA sequencing is 
considered as the gold standard technique (Krypuy et al., 2006).  However, its high cost is 
the main disadvantage (Krypuy et al., 2006).  Accordingly, rapid, simple, low cost and 
high throughput methods are mandatory for scanning purposes and SNP genotyping.  
  
In the current study, we assessed the ability of HRM to detect -1426 C/T SNP, its results 
were in parallel with the RFLP and sequencing methods with no observed discrepancies.  
HRM analysis of PCR products depends on DNA melting in the presence of saturating 
SYTO9, a DNA binding dye (Erali et al., 2008).  Among the three PCR based mutation 
detection methods we used for -1426 C/T SNP genotyping, HRM has many advantages as 
also indicated by Liew et. al. (Liew et al., 2004).  In a close- tube method, the analysis is 
performed immediately once amplification is completed in the same machine.  Thus, 
contamination of the amplified product is eliminated as no further processing nor 
separation steps are required.  Moreover, small amplicons used in HRM allow better 
differentiation for the different genotypes as it maximize the difference in Tm between 
them and also reduces the overall time require for cycling when compared with the 
conventional PCR (Liew et al., 2004; Wittwer et al., 2003).  For example, genotyping 
results can be obtained at maximum 90 minutes of performing the reaction even with high 
sample number (up to 72 sample/ run).  Also, when it was compared with other methods, it 
can be considered as inexpensive molecular technique.  Add to that, with the progress and 
improvement of HRM, no probe –based system (labeled primers) is required.  Finally, the 
used interchelating dye- SYTO9- had low toxicity when compared with other DNA 
binding dyes such as ethidium bromide (Monis et al., 2005). 
 
In HRM, the genotype is determined by melting behavior of each allele.  In our study we 
used different melting curve analyses to discriminate between the different genotypes.  For 
example, while the CC genotype shows a one peak stable melting pattern, the CT genotype 
shows less stable double peak phenotype as clearly seen in the melting curve analysis, 
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figure 3.10.  Other types of melting behavior analysis, used to differentiate between the 
different genotypes, such types include, the normalized fluorescence curve which allow 
visual clustering of different genotypes, as seen in figure 3.11, and amplicon melting 
difference curves figure 3.12, in which samples with genotypes similar to the reference 
genotype cluster around it, while those with different genotypes fall in the opposite side. 
 
In light of the increased role that Par1 polymorphism plays in different diseases, we 
recommend the use of HRM in research areas that require genotyping of-1426 C/T SNP.  
For those laboratories that do not have RT- PCR machine, our modified RFLP method will 
help in screening and genotyping  the -1426 C/T SNP in a more simple and comfortable 
way.  
 
Hardy–Weinberg (HW) law or as known HW equilibrium (HWE), indicates that the 
frequency of two alleles in a single locus are predicted to remain in equilibrium and 
balance from generation to generation in the absence of mutation or selection (Stern, 
1943).  In the current study, no deviation from HWE was seen among cases and controls in 
the two tested polymorphisms.  The allele frequencies among the two groups suggest no 
association between Par 1 polymorphism and recurrent abortion (p = 0.154, p = 1.0 for the 
-506 I/D and -1426 C/T, respectively) (Table 3.4).  The same results (no association) were 
obtained when samples were analyzed according to their geographical distribution (north 
and center district of Palestine). 
 
The frequency of the I allele in the -506 I/D polymorphism in our population was close to 
its frequency in other populations (Altarescu et al., 2010; Arnaud et al., 2000; Dupont et 
al., 2003; Grisaru-Granovsky et al., 2007).  While the I allele has been shown to have a 
protective effect regarding VTE among French males (Arnaud et al., 2000), no evidence 
for a protective effect of this allele from VTE among Californians of European ancestry 
even when analyzed by sex (Pecheniuk et al., 2008).  These contradicting results may be 
related to the small sample size in the later study (114 subjects) when compared with 1462 
subjects in the former one.  The absence of a protective effect of the I allele among French 
females might be related to sex hormones that might cause a decrease in PAR1 expression 
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in vascular cells (Arnaud et al., 2000).  It has been shown that II genotype in -506 I/D 
polymorphism may be an essential predictive factor for EA and was associated with 
developing tumor recurrence (Lurje et al., 2010).  As this polymorphism has no effect on 
the outcome of pregnancy in our study (RA) the effect of such polymorphism may be 
tissue specific and not only sex related. 
 
In -1426 C/T SNP genotyping, the TT homozygous genotype was absent among all 
subjects (Table3.3).  The scarcity of this genotype is not only evident in our study.  The 
study carried out by Grisaru-Granovsky et. al. among the Jewish people did not show this 
genotype (Grisaru-Granovsky et al., 2007), while in Arnaud’s e.t al. study among the 
European people, only one case out of 1464 had this genotype (Arnaud et al., 2000).  Other 
studies, on the other hand, had this genotype but in low frequencies (Martinelli et al., 
2008).  The only study that had an aberrant TT genotype was done by Altarescu and 
colleagues among the Jewish people (Altarescu et al., 2010).  This can be interpreted in 
different ways; studies concerning Par1 polymorphism was carried out among different 
populations, for that, ethnicity may affect the frequency of this genotype.  Concerning 
ethnicity and -1426 C/T, two different studies were carried out on the same ethnic group 
(Jews) (Altarescu et al., 2010; Grisaru-Granovsky et al., 2007).  In these two studies the 
results obtained concerning the TT genotype were totally different, except in the 
heterozygous state.  This difference may be related to the method used in SNP detection.  
While Altarescu et al, used sequencing to detect this SNP (Altarescu et al., 2010), Grisaru-
Granovsky et. al. used RFLP to do so (Grisaru-Granovsky et al., 2007).  Incidentally, 
sequencing is considered the gold standard for genotyping (Krypuy et al., 2006), and in 
fact,  Altarescu et. al. in 2010 reported that for technical reasons, they used sequencing and 
not RFLP in their study.  As we demonstrated earlier in our discussion, we modified the 
RFLP method.  Upon modification, we could easily differentiate between the genotypes 
compared to Arnaud et. al. and the difference in the digestion critiria between Arnaud’s 
article and the Nebcutter web site cause difference in interpreting the different genotype.   
This difference in ease in interpreting the digestion criteria may be the cause of totally 
different distribution of genotypes among the Jews people.  Although it came out to have 
no correlation with RA in our study, the T allele in this polymorphism has been reported to 
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be associated with high rates of liver fibrosis in men suffering from hepatitis C (gender 
related) (Martinelli et al., 2008).  Females carrying the T allele were at increased risk 
concerning PTD (Grisaru-Granovsky et al., 2007).  The TT genotype also correlate with 
low platelets count in patients with Gaucher disease (Altarescu et al., 2010).  This 
discrepancy in its correlation with different disease situation could be gender related,     
tissue specific or different biological process. 
 
 
While our study did not reveal an association between polymorphisms in Par1 at the 5′ 
regulatory region, the role of Par1 polymorphism in the intervening sequence still need to 
be evaluated, since only the T allele of -14 IVS A/T (rs168753)  SNP was reported to be 
associated with decreased platelets PAR1 expression level (Dupont et al., 2003). 
 
In the current study the role of Par1 polymorphisms (rs11267092 and rs32934) at the 
maternal side was evaluated, and this was one of the limitations in our study, the fetal 
factor concerning Par1 polymorphism must be taken in consideration as placentation is a 
complex and shared process between microenvironment (maternal factor) and CTB (fetal 
factor). 
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4.2 Recommendations  
 
In conclusion, little is known and much remains to be learned about the molecular events 
and vital signaling pathways that take place during placentation.  How placental- maternal 
cell type cooperate in an integrated way to control decidual invasion and spiral artery 
remodeling in spatial and temporal manner.  
 
As RA is a frustrating condition for physicians and upsetting for patients, we recommend 
testing Par1 polymorphisms (rs11267092, rs32934 and rs168753) as a fetal factor that may 
lead to RA and evaluation of the -14 IVS A/T SNP (rs168753) before ruling out the Par1 
gene ppolymorphism as a risk factor for RA in our population.  We also recommend the 
use of our methods when screening for Par1 polymorphisms in the 5′ regulatory 
(rs11267092 and rs32934) region in other diseases since they provide simple and easy 
ways for analysis. 
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Recurrent abortion study, relation to Homeostasis 
Questionnaire 
 
Patient Name:                                                                                       Patient ID:            
Parity          G                                                                                           Phone No:  
No. Abortions:                                                                              Age: 
Successive abortions:                                                                            Place: 
Neonatal death:                                                                                                      
Pre‐ maturity:                                                 
Doctor’s Name:                                                       
                                                   
Patient selection:  Recurrent pregnancy loss will be defined as two or more consecutive 
spontaneous abortions. 
Normal control: females with two or more normal deliveries. 
Test which the patient has already done before: 
Test Name Normal  Abnormal 
Factor V
Factor II    
Factor XIII    
Beta fibrinogen    
Anticardiolipn antibody    
Protein S    
Protein C     
Antithrombin III deficiency      
Uterine Shape     
Infectious screen    
Couples karyotyping     
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  إقرار خطي
 
 
 
 
  أنا الموقعة أدناه 
  ........................................................................................................................
أوافق على اخذ عينة دم مني لغرض إجراء بحث يتناول أسباب حدوث الإجھاض المتكرر، وقد تم 
ء البحث من قبل طبيبي المعالج شرح الأھداف من إجرا
ة................................................................................................................./الدكتور
  ....
  
  
  
 
 
  
 elirets rednu nwardhtiw saw ,elpmas doolb elohw ATDE lm5‐3 elpmaS
 .keew eno rof Co4 ta tpek dna nekat saw elpmaS .snoitidnoc
 
 ..……………………… erutangis s’baL
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  عند النساء الفلسطينيات 1raP(علاقة الإجهاض المتكرر مع تعدد أشكال الجين )
  
  عداد: مرفت محمود أبو غزالهإ
  
  إشراف: الدكتور زيدون صلاح
  زياد عابدين .د .أ       
  :  ملخص
  
% مـن النسـاء فـي سـن الإنجـاب خـلال الأشـهر 5صـيب يو  الإجهاض المتكرر من احد مشـاكل الحمـل 
ى من الحمـل.  وبـالرغم مـن وجـود أسـباب كثيـرة للإجهـاض المتكـرر إلا أن السـبب الحقيقـي الثلاثة الأول
  لا يزال مبهما عند نصف الحالات.
فــي نســيج المشــيمة عنــد تكوينهــا فــي الفتــرة الممتــدة بــين  )1RAP(لقــد لــوحظ ارتفــاع نســبة المســتقبل 
ستقبل بعـد ذلـك، ولقـد أثبتـت الدراسـات الأسبوع السابع إلى الأسبوع العاشر من الحمل ثم اختفاء هذا الم
لـه (  msihpromylop) مهـم فـي عمليـة تكـون المشـيمة و أن تعـدد أشـكال هـذا الجـين )1RAP(أن 
علاقة مع بعض مشاكل الحمل، فكان هدف الدراسة الرئيسي إيجاد العلاقة بين تعدد أشكال هذا الجـين 
  و الإجهاض المتكرر. 
 تعرضـت حالـة( 471) و شمال فلسطين، حيث اعتبرت كل امـرأة اشتملت الدراسة على نساء من وسط
أمــا المجموعــة  .مــن حملهــا حالــة مرضــية  الأولــىالــثلاث  الأشــهرفــي  أكثــر أومتكــررين  لاجهاضــين
  مرتين أو أكثر بدون مشاكل تذكر.أنجبن تضم نساء  فكانت142( ) الضابطة
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لتابع لجامعة القـدس فـي أبـو ديـس فـي الفتـرة تّم إجراء هذا البحث في معهد البحوث الصحية و التغذية ا
حيـث تـم عـزل الحمـض النـووي مـن عينـات دم أخـذت مـن المشـاركات فـي  ،0102إلـى  9002الزمنيـة 
 T/C 6241-و   )D/I( noiteleD / noitresnI 605-الدراسـة.  تمـت دراسـة منطقتـي تعـدد الشـكل
 )RCP(اتجـة عـن التفاعـل السلسـلي استخدمت طريقة اخـتلاف طـول القطعـة الن و (1raPفي الجين ) 
فقـد تـم الكشـف  T/C 6241-أمـا  D/I 605-. للكشـف عـن (  )RCP cihpromylop ezisالم سماة
 و الطريقـــة )PLFR(والمســـماة  RCP(عنهـــا بطريقـــة قـــص القطعـــة الناتجـــة عـــن التفاعـــل السلســـلي )
  . (gnicneuqes ANDوتسلسل الحمض النووي ) )MRH(المسماة ذوبان عالي الدقة 
لقـد تـم فـي هـذه الدراسـة إجـراء تعـديل علـى طـرق منشـورة لفحـص الأشـكال المتعـددة لهـذا الجـين وكانـت 
، ولقـد نجحـت هـذه التعـديلات  (1raP هـذه التعـديلات تهـدف إلـى تسـهيل عمليـة فحـص تعـدد أشـكال )
يـزة ( بالـذات مMRH)وكان لطريقة  .حيث كانت الطرق المستخدمة أسهل و أفضل من الطرق السابقة
  . والتكلفةتوفر الوقت و الجهد  أنهاكبيرة من حيث 
 أيوالإجهـــاض المتكـــرر  حيـــث لـــم يشـــاهد  )1raP(لـــم تثبـــت هـــذه الدراســـة وجـــود علاقـــة بـــين أشـــكال 
  Iوكـان تـردد الاليـل  grebnieW – ydraHلعـن التـوازن الطبيعـي  )1raP( اخـتلاف لتعـدد أشـكال
وكانـت  .ضـية و المجموعـة الضـابطة ، علـى التـواليللحالـة المر  673.0و   823.0هو  D/I605-في
 Tبينما كان تردد الاليل  6.0 – 1.1( )551.0 p()= (IC)و فترة الثقة   8.0= (ROنسبة الخلاف )
  والمجموعـة الضـابطة علـى التـوالي. للحالـة المرضـية 900.0و   210.0هـو  T/C 6241-فـي 
 . )0.1p(  )8.1-8.0(=( IC)و فترة الثقة   3.1(=RO)وكانت نسبة الخلاف 
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مــع الإجهــاض المتكــرر إلا أننــا نــثمن دراســتنا،  )1raP( وبــالرغم مــن عــدم وجــود علاقــة لتعــدد أشــكال
خصوصا أن هذا الجين له علاقـة مـع  )1raP(حيث قمنا بتطوير وسائل أسهل و أوفر لفحص أشكال 
اسـة لـم تثبـت العلاقـة مـع وبمـا أن هـذه الدر   .كثير من الأمـراض حسـب مـا ورد فـي عـدة دراسـات سـابقة
مـع مشـاكل  raP( )1الإجهاض المتكرر في المجتمع الفلسطيني بالرغم من وجـود علاقـة لتعـدد أشـكال 
أخـرى فـي الحمـل وكـذلك مـع أمـراض أخـرى فـي مجتمعـات مختلفـة، فـان السـؤال لا يـزال مفتوحـا لإيجـاد 
تكــرر فــي مجتمعنــا إذا تــم مــع مشــاكل أخــرى للحمــل والإجهــاض الم  )1raP(علاقــة بــين تعــدد أشــكال
  .فحص الجنين أيضا وليس فقط الأم
 
 
 
